Active Ingredient History

  • Now
Camptothecin (CPT) is a topoisomerase inhibitor. It was discovered in 1966 by M. E. Wall and M. C. Wani in systematic screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata, a tree native to China used in traditional Chinese medicine. It has been used clinically more recently in China for the treatment of gastrointestinal tumors. CPT showed anticancer activity in preliminary clinical trials, especially against breast, ovarian, colon, lung, and stomach cancers. However, it has low solubility and adverse effects have been reported when used therapeutically, so synthetic and medicinal chemists have developed numerous syntheses of camptothecin and various derivatives to increase the benefits of the chemical, with good results. Four CPT analogues have been approved and are used in cancer chemotherapy today, topotecan, irinotecan, belotecan, and trastuzumab deruxtecan. Camptothecin has also been found in other plants including Chonemorpha fragrans.   Wikipedia

More Chemistry
20-o-(nalpha-(4-(3-o-methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecin | 20-o-(nalpha-(4-(3-o-methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecin hydrochloride | 20(s)-camptothecin | 21,22-secocamptothecin-21-oic acid lactone | bay383441 | bay 383441 | bay 38-3441 | bay-383441 | bay-38-3441 | bay 56-3722 | camptothecin | (+)-camptothecin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue